Sorry, you need to enable JavaScript to visit this website.

Health Data Notice

 

Health Data Notice for Washington & Nevada Residents

Last Updated: August 28, 2024

This Health Data Notice (“Health Data Notice”) governs the websites (each a “Site”), apps (each an “App”), offline locations or services (collectively, the “Services”) owned and operated by Nestlé Health Science U.S., or its affiliates and subsidiaries (referred to herein as “Nestlé Health Science,” “we,” “us,” or “our” as applicable) that display, reference, or link to this Health Data Notice. This Health Data Notice supplements our Privacy Policy and applies to “Consumer Health Data” subject to Washington and Nevada privacy laws (collectively, “health data privacy laws”). 

CONSUMER HEALTH DATA WE COLLECT

We collect the following categories of Consumer Health Data:

•    Information about your health-related conditions, symptoms, status, diagnoses, testing, or treatments, including prescription information.
•    Information about your bodily functions.
•    Information that could identify your attempt to seek health related services.
•    Other information that may be used to infer or derive data related to the above or other health information.

SOURCES OF CONSUMER HEALTH DATA

As described further in the “How We Collect Personal Information” section of the Privacy Policy, we collect Consumer Health Data directly from you, from your interactions with our Services, from third parties, including Affiliates (defined below), and from publicly available sources.

WHY WE COLLECT AND USE CONSUMER HEALTH DATA

We may use the categories of Consumer Health Data described above for the following purposes:

Communicating with You. We use Consumer Health Data to respond to your questions and comments when you communicate with us through links or pages in the Services, such as the "Contact Us" feature.

Processing Your Transactions. If you purchase products from us on or through the Services, we use your Consumer Health Data to process your purchase, confirm your order, and deliver the items to you.

Administering the Services. We use your Consumer Health Data to administer the Services and carry out any other business activities.

Abandoned Cart. We use technologies to help keep track of the items you put into your cart, including when you have abandoned your cart, and use this information to determine when to send a cart reminder via SMS or other channels.

Providing You with Personalized Recommendations. If you choose to complete assessments in the Services, we will use your Consumer Health Data to send you personalized product recommendations and other information that may be of interest to you.

Performing Analyses. We use your Consumer Health Data to perform business analyses or for other purposes designed to improve the quality of our business and the Services we offer.

Preventing and Detecting Fraud and Other Crimes. We use your Consumer Health Data to help prevent and detect fraud and other crimes that might be committed using or against the Services. We may use your Consumer Health Data to investigate possible violations of and enforce our contracts.

Managing and Operating Our IT Systems. We use your Consumer Health Data to help us in troubleshooting, testing, maintaining, and protecting our IT systems, including our Sites.

Complying with Legal and Regulatory Obligations. We use your Consumer Health Data to comply with our legal and regulatory obligations, which arise from time to time. We may also use your Consumer Health Data to protect our or others’ rights, privacy, safety or property, and/or that of our affiliates. We do this to protect our business assets and to comply with our legal obligations.

Promotions, Surveys, Sweepstakes, and Message Boards. We use your Consumer Health Data to enable you to voluntarily participate in features such as promotions, surveys, polls, sweepstakes, and message boards in the Services.

Creating Aggregate or Anonymized Information. We use Consumer Health Data you provide to us regarding the Services to provide product feedback to our customers in aggregated form. We may also use aggregate Consumer Health Data to analyze general trends in the use of the Services. 

As Otherwise Permitted by Law or as We May Notify You. We may also use Consumer Health Data you provide to us for other purposes as disclosed at the time you provide your information or otherwise with your consent.

WITH WHOM DO WE SHARE CONSUMER HEALTH DATA

As defined by health data privacy laws, we share Consumer Health Data with the categories of third parties listed below. We will obtain your consent before sharing your Consumer Health Data.

Affiliates. We are affiliated with several other health and wellness brands (collectively, our “Affiliates”). We may share your Consumer Health Data with our Affiliates to send you promotions, information about sales and offers, and newsletters in which you have indicated interest and for legal and other business purposes.

Business Partners. We may share your Consumer Health Data with companies with whom we partner to offer goods or services, including jointly provided products, or sweepstakes, contests, and similar and promotions.

Competent Governmental and Public Authorities. We may share your Consumer Health Data with governmental authorities if we believe disclosure is necessary or appropriate to prevent physical harm or financial loss or in connection with an investigation of suspected or actual illegal activity or a violation of our Terms and Conditions (posted at the footer of our Site) or other contracts.

Third Parties Pursuant to Legal Process. We may share your Consumer Health Data to the extent necessary to respond to subpoenas, court orders, or other legal process; in response to a request for cooperation from law enforcement or a government agency; or to otherwise comply with our other legal and regulatory obligations.

Other Third Parties. We may share your Consumer Health Data when we believe in good faith that disclosure is necessary to protect our rights, protect your safety or the safety of others, including to allow us to pursue available remedies and limit the damage we may sustain. To the extent we share your Consumer Health Data with other third parties, we will do so in accordance with health data privacy laws.

HOW TO EXERCISE YOUR RIGHTS

Health data privacy laws provide covered individuals with certain rights to access, delete, or withdraw consent relating to their Consumer Health Data, subject to certain exceptions.

If you would like to exercise the rights outlined above, please contact us by phone at 1-833-AIM2KNO (1-833-246-2566) or by email at usnhscpharmadataprivacy@us.nestle.com. If you send a request by email, please write “Washington Consumer Health Data Request” or “Nevada Consumer Health Data Request” in the subject line and state which rights you seek to exercise in the body of your message. We may take steps to verify your identity before responding to your request by asking you a series of questions about your previous interactions with us.

If your request to exercise a right under health data privacy laws is denied, you may appeal that decision by emailing us at NHScLegal@us.nestle.com. If your appeal is unsuccessful, you can raise a concern or lodge a complaint with the Nevada or Washington State Attorney General, as applicable. NV (CSU Complaints & FAQ); WA (https://www.atg.wa.gov/file-complaint).

REVISIONS TO THIS HEALTH DATA NOTICE

We reserve the right, at our sole discretion, to change, modify, add, remove, or otherwise revise portions of this Health Data Notice at any time. When we do, we will post the change(s) on our Services. Your continued use of our products and Services following the posting of changes to these terms means you accept these changes. If we change this Health Data Notice in a material or substantive way, we will provide appropriate notice to you.

HOW TO CONTACT US

If you have any questions or concerns about this Health Data Notice or the practices described herein, you may contact us by calling 1-833-AIM2KNO (1-833-246-2566), by emailing usnhscpharmadataprivacy@us.nestle.com, or by mail to Nestlé Health Science, Attn: Legal, 1007 US Highway 202/206, Building JR2, Suite E102, Bridgewater, NJ 08807.

​ 

References: 1. Garey KW, Jo J, Gonzales-Luna AJ, et al. Assessment of quality of life among patients with recurrent Clostridioides difficile infection treated with investigational oral microbiome therapeutic SER-109. JAMA Netw Open. 2023;6(1):e2253570. doi:10.1001/jamanetworkopen.2022.53570 2. Lurienne L, Bandinelli P-A, Galvain T, Coursel C-A, Oneto C, Feuerstadt P. Perception of quality of life in people experiencing or having experienced a Clostridioides difficile infection: a US population survey. J Patient Rep Outcomes. 2020;4(1):14. doi:10.1186/s41687-020-0179-1 3. Boustany A, Feuerstadt P, Tillotson G. The 3 Ds: depression, dysbiosis, and Clostridioides difficile. Adv Ther. 2024;41(11):3982-3995. doi:10.1007/s12325-024-02972-0 4. Feuerstadt P, Theriault N, Tillotson G. The burden of CDI in the United States: a multifactorial challenge. BMC Infect Dis. 2023;23(132):1-8. doi:10.1186/s12879-023-08096-0 5. U.S. Department of Health and Human Services. Antibiotic resistance threats in the United States: 2019. Accessed March 4, 2025. https://www.cdc.gov/antimicrobial-resistance/media/pdfs/2019-ar-threats-report-508.pdf 6. Centers for Disease Control and Prevention. Clostridioides difficile infection (CDI) surveillance. Updated June 26, 2024. Accessed June 17, 2025. https://www.cdc.gov/healthcare-associated-infections/php/haic-eip/cdiff.html?CDC_AAref_Val=https://www.cdc.gov/hai/eip/cdiff-tracking.html 7. Song JH, Kim YS. Recurrent Clostridium difficile infection: risk factors, treatment, and prevention. Gut Liver. 2019;13(1):16-24. doi:10.5009/gnl18071 8. Feuerstadt P, Stong L, Dahdal DN, Sacks N, Lang K, Nelson WW. Healthcare resource utilization and direct medical costs associated with index and recurrent Clostridioides difficile infection: a real-world data analysis. J Med Econ. 2020;23(6):603-609. doi:10.1080/13696998.2020.1724117 9. Feuerstadt P, Louie TJ, Lashner B, et al. SER-109, an oral microbiome therapy for recurrent Clostridioides difficile infection. N Engl J Med. 2022;386(3):220-229. doi:10.1056/NEJMoa2106516 10. MacDonald LC, Gerding DN, Johnson S, et al. Clinical Practice Guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018;66(7):e1-e48. doi:10.1093/cid/cix1085 11. Fu Y, Luo Y, Grinspan AM. Epidemiology of community-acquired and recurrent Clostridioides difficile infection. Ther Adv Gastroenterol. 2021;14:1-11. doi:10.1177/17562848211016248 12. Rodrigues R, Barber GE, Ananthakrishnan AN. A comprehensive study of costs associated with recurrent Clostridium difficile infection. Infect Control Hosp Epidemiol. 2017;38(2):196-202. doi:10.1017/ice.2016.246 13. Hengel RL, Schroeder CP, Jo J, et al. Recurrent Clostridioides difficile infection worsens anxiety-related patient-reported quality of life. J Patient Rep Outcomes. 2022;6(1):49. doi:10.1186/s41687-022-00456-9 14. Khanna S, Sims M, Louie TJ, et al. SER-109: An oral investigational microbiome therapeutic for patients with recurrent Clostridioides difficile infection (rCDI). Antibiotics (Basel). 2022;11(9):1234. doi:10.3390/antibiotics11091234 15. Dificid [Prescribing Information]. Rahway, NJ: Merck Sharp & Dohme LLC. 06/2022. 16. McGovern BH, Ford CB, Henn MR, et al. SER-109, an investigational microbiome drug to reduce recurrence after Clostridioides difficile infection: lessons learned from a phase 2 trial. Clin Infect Dis. 2021;72(12):2132-2140. doi:10.1093/cid/ciaa387 17. Jain N, Umar TP, Fahner A-F, Gibietis V. Advancing therapeutics for recurrent clostridioides difficile infections: an overview of vowst’s FDA approval and implications. Gut Microbes. 2023;15(1):2232137. doi:10.1080/19490976.2023.2232137 18. Normington C, Chilton CH, Buckley AM. Clostridioides difficile infections; new treatments and future perspectives. Curr Opin Gastroenterol. 2024;40(1):7-13. doi:10.1097/MOG.0000000000000989 19. Vincent C, Miller MA, Edens TJ, et al. Bloom and bust: intestinal microbiota dynamics in response to hospital exposures and Clostridium difficile colonization or infection. Microbiome. 2016;4:12. doi:10.1186/s40168-016-0156-3 20. Chilton CH, Pickering DS, Freeman J. Microbiologic factors affecting Clostridium difficile recurrence. Clin Microbiol Infect. 2018;24(5):476-482. doi:10.1016/j.cmi.2017.11.017 21. Safety alert regarding use of fecal microbiota for transplantation and risk of serious adverse events likely due to transmission of pathogenic organisms. Safety alert. March 12, 2020. Accessed March 4, 2025. https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/safety-alert-regarding-use-fecal-microbiota-transplantation-and-risk-serious-adverse-events-likely 22. Stallhofer J, Steube A, Katzer K, Stallmach A. Microbiota-based therapeutics as new standard-of-care treatment for recurrent Clostridioides difficile infection. Visc Med. 2024;40(2):82-91. doi:10.1159/000535851 23. U.S. Department of Health and Human Services. Enforcement policy regarding investigational new drug requirements for use of fecal microbiota for transplantation to treat Clostridioides difficile infection not responsive to standard therapies. Accessed July 10, 2025. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enforcement-policy-regarding-investigational-new-drug-requirements-use-fecal-microbiota 24. The OpenBiome Foundation. Accessed July 10, 2025. https://openbiome.org/fmt-update-future-directions/ 25. Grosen AK, Mikkelsen S, Hindhede LA, et al. Effects of clinical donor characteristics on the success of faecal microbiota transplantation for patients in Denmark with Clostridioides difficile infection: a single-centre, prospective cohort study. Lancet Microbe. 2025;6(5):101034. doi: 10.1016/j.lanmic.2024.101034 26. Porcari S, Benech N, Valles-Colomer M, et al. Key determinants of success in fecal microbiota transplantation: From microbiome to clinic. Cell Host Microbe. 2023;31(5):712-733. doi: 10.1016/j.chom.2023.03.020 27. Gupta S, Mullish BH, Allegretti JR. Fecal microbiota transplantation: the evolving risk landscape. Am J Gastroenterol. 2021;00:1–10. doi: 10.14309/ajg.0000000000001075 28. Kelly CR, Fischer M, Allegretti JR, et al. ACG Clinical Guidelines: prevention, diagnosis, and treatment of Clostridioides difficile infections. Am J Gastroenterol. 2021;116(6):1124-1147. https://doi.org/10.14309/ajg.0000000000001278 29. Peery AF, Kelly CR, Kao D, et al. AGA Clinical Practice Guideline on fecal microbiota-based therapies for select gastrointestinal diseases. Gastroenterology. 2024;166(3):409-434. doi:10.1053/j.gastro.2024.01.008